Innovations in Molecular Treatment of Hematological Malignancies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 168
Special Issue Editor
2. SMEL Genetics-SSD Cytogenetics and Medical Genetics, Ospedale Macchi-ASST Settelaghi, Viale Borri 57, 21100 Varese, Italy
Interests: mitochondrial DNA; mitochondrial disorders; myeloproliferative neoplasms; inherited thrombophilias; nonsyndromic hearing loss; pharmacogenetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematologic malignancies represent a field of innovation in therapeutics, with the use of new drugs with new characteristics among anticancer agents. Personalized therapy of the individual patient starts from the concept of labeling the neoplasm according to its molecular profile. New therapies in hematology involve approaches based on various techniques, including the use of new targeted drugs, new immunotherapies (monoclonal antibodies), and hematopoietic stem cell transplantation. The latter approach involves autologous and allogeneic hematopoietic stem cell transplantation procedures, from an HLA-identical family donor, bank donor, or haploidentical donor. Innovative therapies also include CAR-Ts (Chimeric Antigens Receptor) and the use of drugs targeted against mutated enzymes/proteins (e.g., Ibrutinib). In this Special Issue, we encourage the submission of papers on new therapeutic approaches in hematological malignancies based on new cell lines, immunotherapy or new targeted drugs, and other innovative approaches.
Dr. Francesco Pallotti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematologic malignancies
- target drugs
- new immunotherapies
- hematopoietic stem cell transplantation
- CAR-Ts
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: The interplay between the DNA damage response (DDR) network and the mitogen-activated protein kinase (MAPK) signaling pathway in multiple myeloma.
Authors: Panagiotis Malamos, Christina Papanikolaou, Meletios A. Dimopoulos, Evangelos Terpos and Vassilis L. Souliotis
Abstract: The DNA Damage Response (DDR) network and the mitogen-activated protein kinase (MAPK) signaling pathway are crucial mechanisms for the survival of all living beings. An accumulating body of evidence suggests that there is a crosstalk between these two systems, thus favoring the appropriate functioning of multicellular organisms. On the other hand, aberrations within these mechanisms are thought to play a vital role in the onset and progression of several diseases, including cancer, as well as in the emergence of drug resistance. Here, we provide an overview of the current knowledge regarding alterations in the DDR machinery and the MAPK signaling pathway, as well as abnormalities in the DDR-MAPK functional crosstalk in multiple myeloma, the second most common hematologic malignancy. We also present the latest advances in the development of anti-myeloma drugs targeting crucial DDR- and MAPK-associated molecular components. These data could potentially be exploited to discover new therapeutic targets and effective biomarkers, as well as for the design of novel clinical trials. Interestingly, they might provide a new approach to increase the efficacy of anti-myeloma therapy by combining drugs targeting the DDR network and the MAPK signaling pathway.
